582 related articles for article (PubMed ID: 33572274)
21. Jeopardy of COVID-19: Rechecking the Perks of Phytotherapeutic Interventions.
Saha P; Bose S; Srivastava AK; Chaudhary AA; Lall R; Prasad S
Molecules; 2021 Nov; 26(22):. PubMed ID: 34833873
[TBL] [Abstract][Full Text] [Related]
22. SARS-CoV-2 Infection of Human Neurons Is TMPRSS2 Independent, Requires Endosomal Cell Entry, and Can Be Blocked by Inhibitors of Host Phosphoinositol-5 Kinase.
Kettunen P; Lesnikova A; Räsänen N; Ojha R; Palmunen L; Laakso M; Lehtonen Š; Kuusisto J; Pietiläinen O; Saber SH; Joensuu M; Vapalahti OP; Koistinaho J; Rolova T; Balistreri G
J Virol; 2023 Apr; 97(4):e0014423. PubMed ID: 37039676
[TBL] [Abstract][Full Text] [Related]
23. Cathepsin L in COVID-19: From Pharmacological Evidences to Genetics.
Gomes CP; Fernandes DE; Casimiro F; da Mata GF; Passos MT; Varela P; Mastroianni-Kirsztajn G; Pesquero JB
Front Cell Infect Microbiol; 2020; 10():589505. PubMed ID: 33364201
[TBL] [Abstract][Full Text] [Related]
24. Emergence, Transmission, and Potential Therapeutic Targets for the COVID-19 Pandemic Associated with the SARS-CoV-2.
Patil AM; Göthert JR; Khairnar V
Cell Physiol Biochem; 2020 Aug; 54(4):767-790. PubMed ID: 32830930
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19).
Nayak SK
Mini Rev Med Chem; 2021; 21(6):689-703. PubMed ID: 33208074
[TBL] [Abstract][Full Text] [Related]
26. Epstein-Barr Virus Lytic Replication Induces ACE2 Expression and Enhances SARS-CoV-2 Pseudotyped Virus Entry in Epithelial Cells.
Verma D; Church TM; Swaminathan S
J Virol; 2021 Jun; 95(13):e0019221. PubMed ID: 33853968
[TBL] [Abstract][Full Text] [Related]
27. SARS-CoV-2 promotes RIPK1 activation to facilitate viral propagation.
Xu G; Li Y; Zhang S; Peng H; Wang Y; Li D; Jin T; He Z; Tong Y; Qi C; Wu G; Dong K; Gou J; Liu Y; Xiao T; Qu J; Li L; Liu L; Zhao P; Zhang Z; Yuan J
Cell Res; 2021 Dec; 31(12):1230-1243. PubMed ID: 34663909
[TBL] [Abstract][Full Text] [Related]
28. Statins in COVID-19: is there any foundation?
Lima Martínez MM; Contreras MA; Marín W; D'Marco L
Clin Investig Arterioscler; 2020; 32(6):278-281. PubMed ID: 32718669
[TBL] [Abstract][Full Text] [Related]
29. Repositioning of histamine H
Ge S; Wang X; Hou Y; Lv Y; Wang C; He H
Eur J Pharmacol; 2021 Apr; 896():173897. PubMed ID: 33497607
[TBL] [Abstract][Full Text] [Related]
30. Identification of SARS-CoV-2 Receptor Binding Inhibitors by In Vitro Screening of Drug Libraries.
David AB; Diamant E; Dor E; Barnea A; Natan N; Levin L; Chapman S; Mimran LC; Epstein E; Zichel R; Torgeman A
Molecules; 2021 May; 26(11):. PubMed ID: 34072087
[TBL] [Abstract][Full Text] [Related]
31. A Novel Glucocorticoid and Androgen Receptor Modulator Reduces Viral Entry and Innate Immune Inflammatory Responses in the Syrian Hamster Model of SARS-CoV-2 Infection.
Rocha SM; Fagre AC; Latham AS; Cummings JE; Aboellail TA; Reigan P; Aldaz DA; McDermott CP; Popichak KA; Kading RC; Schountz T; Theise ND; Slayden RA; Tjalkens RB
Front Immunol; 2022; 13():811430. PubMed ID: 35250984
[TBL] [Abstract][Full Text] [Related]
32. Computational and in vitro experimental analyses of the anti-COVID-19 potential of Mortaparib and MortaparibPlus.
Kumar V; Sari AN; Meidinna HN; Dhanjal JK; Subramani C; Basu B; Kaul SC; Vrati S; Sundar D; Wadhwa R
Biosci Rep; 2021 Oct; 41(10):. PubMed ID: 34647577
[TBL] [Abstract][Full Text] [Related]
33. Potential antiviral activity of isorhamnetin against SARS-CoV-2 spike pseudotyped virus in vitro.
Zhan Y; Ta W; Tang W; Hua R; Wang J; Wang C; Lu W
Drug Dev Res; 2021 Dec; 82(8):1124-1130. PubMed ID: 33847382
[TBL] [Abstract][Full Text] [Related]
34. Infectious Clones Produce SARS-CoV-2 That Causes Severe Pulmonary Disease in Infected K18-Human ACE2 Mice.
Liu X; Zaid A; Freitas JR; McMillan NA; Mahalingam S; Taylor A
mBio; 2021 Apr; 12(2):. PubMed ID: 33879586
[TBL] [Abstract][Full Text] [Related]
35. Variants in ACE2; potential influences on virus infection and COVID-19 severity.
Bakhshandeh B; Sorboni SG; Javanmard AR; Mottaghi SS; Mehrabi MR; Sorouri F; Abbasi A; Jahanafrooz Z
Infect Genet Evol; 2021 Jun; 90():104773. PubMed ID: 33607284
[TBL] [Abstract][Full Text] [Related]
36. Possible inhibition of GM-CSF production by SARS-CoV-2 spike-based vaccines.
Li J; Wang P; Tracey KJ; Wang H
Mol Med; 2021 May; 27(1):49. PubMed ID: 34022793
[TBL] [Abstract][Full Text] [Related]
37. Angiotensin-converting enzyme 2 (ACE2): COVID 19 gate way to multiple organ failure syndromes.
Loganathan S; Kuppusamy M; Wankhar W; Gurugubelli KR; Mahadevappa VH; Lepcha L; Choudhary AK
Respir Physiol Neurobiol; 2021 Jan; 283():103548. PubMed ID: 32956843
[TBL] [Abstract][Full Text] [Related]
38. Mapping the SARS-CoV-2-Host Protein-Protein Interactome by Affinity Purification Mass Spectrometry and Proximity-Dependent Biotin Labeling: A Rational and Straightforward Route to Discover Host-Directed Anti-SARS-CoV-2 Therapeutics.
Terracciano R; Preianò M; Fregola A; Pelaia C; Montalcini T; Savino R
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33430309
[TBL] [Abstract][Full Text] [Related]
39. Binding and entering: COVID finds a new home.
Vu MN; Menachery VD
PLoS Pathog; 2021 Aug; 17(8):e1009857. PubMed ID: 34460863
[TBL] [Abstract][Full Text] [Related]
40. SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and Treatments.
Canedo-Marroquín G; Saavedra F; Andrade CA; Berrios RV; Rodríguez-Guilarte L; Opazo MC; Riedel CA; Kalergis AM
Front Immunol; 2020; 11():569760. PubMed ID: 33362758
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]